医学
间质性肺病
肺功能测试
支气管镜检查
肺
呼吸系统
弥漫性肺泡损伤
病理
内科学
放射科
急性呼吸窘迫
作者
Linna Jiang,Chunlei Shao,Wenjiao Jiang
出处
期刊:Chinese Journal of Asthma
日期:2019-11-05
卷期号:39 (21): 1665-1669
标识
DOI:10.3760/cma.j.issn.1673-436x.2019.21.012
摘要
Interstitial lung disease (ILD) is a group of diffuse lung diseases that mainly affect the pulmonary interstitium and alveolar space, resulting in the loss of alveolar-capillary functional units, so early diagnosis is the key to effective management of ILD.Thoracic high-resolution CT, pulmonary function tests, bronchoscopy and lung biopsy are effective means for diagnosis of ILD, and can assess disease severity and treatment efficacy.But it is costly, radiant and invasive.Studies have found that alveolar type Ⅱ cell surface antigen 6 (KL-6) is a promising serological marker for ILD, which is significantly associated with the occurrence, progression, drug efficacy and prognosis of ILD.It is also found that KL-6 also plays an important role in other respiratory diseases.This article reviews the research progress of KL-6 in respiratory diseases.
Key words:
KL-6; Lung diseases, interstitial
科研通智能强力驱动
Strongly Powered by AbleSci AI